These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 17959712)
1. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Pattarozzi A; Gatti M; Barbieri F; Würth R; Porcile C; Lunardi G; Ratto A; Favoni R; Bajetto A; Ferrari A; Florio T Mol Pharmacol; 2008 Jan; 73(1):191-202. PubMed ID: 17959712 [TBL] [Abstract][Full Text] [Related]
2. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Porcile C; Bajetto A; Barbieri F; Barbero S; Bonavia R; Biglieri M; Pirani P; Florio T; Schettini G Exp Cell Res; 2005 Aug; 308(2):241-53. PubMed ID: 15921680 [TBL] [Abstract][Full Text] [Related]
3. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Huang Y; Li X; Jiang J; Frank SJ Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991 [TBL] [Abstract][Full Text] [Related]
4. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Darmoul D; Gratio V; Devaud H; Peiretti F; Laburthe M Mol Cancer Res; 2004 Sep; 2(9):514-22. PubMed ID: 15383630 [TBL] [Abstract][Full Text] [Related]
5. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Porcile C; Bajetto A; Barbero S; Pirani P; Schettini G Ann N Y Acad Sci; 2004 Dec; 1030():162-9. PubMed ID: 15659794 [TBL] [Abstract][Full Text] [Related]
6. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor. Nicholl SM; Roztocil E; Davies MG J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933 [TBL] [Abstract][Full Text] [Related]
7. Activation of the calcium-sensing receptor by high calcium induced breast cancer cell proliferation and TRPC1 cation channel over-expression potentially through EGFR pathways. El Hiani Y; Lehen'kyi V; Ouadid-Ahidouch H; Ahidouch A Arch Biochem Biophys; 2009 Jun; 486(1):58-63. PubMed ID: 19332022 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. Greco S; Muscella A; Elia MG; Salvatore P; Storelli C; Mazzotta A; Manca C; Marsigliante S J Cell Physiol; 2003 Aug; 196(2):370-7. PubMed ID: 12811831 [TBL] [Abstract][Full Text] [Related]
9. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164 [TBL] [Abstract][Full Text] [Related]
11. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Boerner JL; Gibson MA; Fox EM; Posner ED; Parsons SJ; Silva CM; Shupnik MA Mol Endocrinol; 2005 Nov; 19(11):2660-70. PubMed ID: 15976008 [TBL] [Abstract][Full Text] [Related]
13. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183 [TBL] [Abstract][Full Text] [Related]
14. SDF-1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent, cytosolic tyrosine kinase Pyk2. Massa A; Casagrande S; Bajetto A; Porcile C; Barbieri F; Thellung S; Arena S; Pattarozzi A; Gatti M; Corsaro A; Robello M; Schettini G; Florio T Ann N Y Acad Sci; 2006 Dec; 1090():385-98. PubMed ID: 17384283 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
18. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343 [TBL] [Abstract][Full Text] [Related]
19. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492 [TBL] [Abstract][Full Text] [Related]
20. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Piechocki MP; Yoo GH; Dibbley SK; Lonardo F Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]